Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1721d75f5bf603447ec5a26b5c1c0be0 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2217-075 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P21-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P21-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-70503 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-705 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K7-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P15-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P17-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P21-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P21-08 |
filingDate |
1998-10-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_44782cd25f153c99a18f55697a40c7c2 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_25e4aa073bde581b71e62dc0d3e19a33 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ed0550393e58a8c253562a282bcd25df http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cbc926ccee50eba536b13027005fb660 |
publicationDate |
2011-07-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
EP-2343316-A1 |
titleOfInvention |
Ligand binding site of RAGE and uses thereof |
abstract |
The present method provides for an isolated peptide having an amino acid sequence corresponding to the amino acid sequence of a V-domain of a receptor for advanced glycation end product (RAGE). The present invention also provides for an isolated peptide having an amino acid sequence A-Q-N-I-T-A-R-I-G-E-P-L-V-L-K-C-K-G-A-P-K-K-P-P-Q-R-L-E-W-K (Seq. ID No. 1). The present invention provides for a pharmaceutical composition comprising a therapeutically effect amount of an isolated peptide having an amino acid sequence corresponding to the amino acid sequence of a V-domain of RAGE. The present invention also provides for a method for inhibiting interaction of an amyloid-β peptide with a receptor for advanced glycation end product which is on the surface of a cell, which comprises contacting the cell with the peptide or a functionally equivalent agent, wherein the peptide or agent is capable of inhibiting interaction of the amyloid-β peptide with the receptor for advanced glycation end product, and the peptide or agent is present in an amount effective to inhibit interaction of the amyloid-β peptide with the receptor for advanced glycation end product. |
priorityDate |
1997-10-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |